Patrick Wright, MD
Pulmonary Disease · Minneapolis, MNNPI 1811917164
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,148 of the $10,487 with a category attached, or 77.7%. Regeneron Healthcare Solutions, Inc. accounts for 90.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $9,534 and has fallen 99.5% since, to $46 in 2024. Among pulmonary disease clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 28 payments — averaging $374.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$10K
- Shionogi Inc$814
- Insmed, Inc.$49
- Inspire Medical Systems, Inc.$46
- Philips North America LLC$26
- Jazz Pharmaceuticals Inc.$19
- plus $30 from 2 others
Across 115 payments — averaging $7015.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$358K
- Merck$143K
- Shionogi Inc$136K
- Novartis$74K
- Boehringer Ingelheim$45K
- Harmony Biosciences LLC$26K
- plus $25K from 1 others
What the payments were for
- Consulting fees$8,14878%
- Travel & lodging$1,51814%
- Food & beverage$7727%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 13 | $9,504 |
| Shionogi Inc | 7 | $814 |
| Insmed, Inc. | 3 | $49 |
| Inspire Medical Systems, Inc. | 1 | $46 |
| Philips North America LLC | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $16 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$9,256
How this compares
$10,487 in reported general payments places this provider in the 90th percentile of 261 pulmonary disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sodium Oxybate | 25 | $457,477 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 305 | $259,024 |
| OfevNintedanib Esylate | 11 | $130,859 |
| Breo ElliptaFluticasone/Vilanterol | 148 | $76,339 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 95 | $19,168 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $18,392 |
| Wixela InhubFluticasone Propion/Salmeterol | 50 | $14,886 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $13,107 |
| Spiriva HandihalerTiotropium Bromide | 11 | $11,925 |
| Spiriva RespimatTiotropium Bromide | 15 | $10,874 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $10,651 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $8,286 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 28 | $6,051 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 175 | $6,011 |
| Advair DiskusFluticasone Propion/Salmeterol | 14 | $4,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $16 | $154,84053 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $14 | $26,67844 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 261 pulmonary disease providers in Minnesota.
Other pulmonary disease in Minneapolis
- Marshall HertzMinneapolis$289K
- David IngbarMinneapolis$272K
- Jonathan HovdaMinneapolis$139K
- Hyun KimMinneapolis$77K
- Grady HedstromMinneapolis$50K
- Joseph KeenanMinneapolis$37K
- Mitchell KayeMinneapolis$24K
- Jennifer WongMinneapolis$12K
- Abdallah AbboudMinneapolis$9K
- Abbie BegnaudMinneapolis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.